The clinical stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF) has advanced its Phase 1 metastatic advanced solid tumours (MAST) trial evaluating the safety of novel cancer-killing oncolytic virus CF33-hNIS (VAXINIA) to the next cohort of the intravenous (IV) arms of both the monotherapy and combination study.